[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335902-105":59,"doc-detail-335902-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prognostic-relevance-of-clonal-hematopoiesis-in-myeloid-neoplastic-transformation-in-patients-with-follicular-lymphoma-treated-with-radioimmunotherapy-abstract-received-june-13-2023","Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy - Abstract - Received June 13, 2023","","While radioisotope therapies advance cancer care, therapy-related myeloid neoplasms (t-MN) remain concerning. A retrospective cohort assessed clonal hematopoiesis (CH) in 58 heavily pre-treated relapsed follicular lymphoma patients receiving radioimmunotherapy (RIT). CH prevalence rose from 46% before RIT to 67% during RIT and subsequent therapies. Fourteen patients (24%) developed t-MN, with higher variant allele fraction and clonal complexity. t-MN showed higher mutant clonal burden, extensive chromosomal abnormalities, and very short post-diagnosis median survival of 0.9 months, highlighting genotoxic stressors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prognostic-relevance-of-clonal-hematopoiesis-in-myeloid-neoplastic-transformation-in-patients-with-follicular-lymphoma-treated-with-radioimmunotherapy-abstract-received-june-13-2023/335902/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prognostic-relevance-of-clonal-hematopoiesis-in-myeloid-neoplastic-transformation-in-patients-with-follicular-lymphoma-treated-with-radioimmunotherapy-abstract-received-june-13-2023/335902.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study hypothesis about clonal hematopoiesis and t-MN after RIT?","Question",{"text":112,"@type":113},"The study hypothesized that clonal hematopoiesis is prevalent in relapsed follicular lymphoma, is associated with therapy-related myeloid neoplasms, and that radiation from radioimmunotherapy contributes to clonal progression and worsened outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did CH prevalence change after radioimmunotherapy in this cohort?",{"text":117,"@type":113},"CH prevalence increased from 46% prior to RIT to 67% during RIT and subsequent therapies in paired samples.",{"name":119,"@type":110,"acceptedAnswer":120},"What clinical and genomic features distinguished patients who developed t-MN?",{"text":121,"@type":113},"Patients with t-MN had a higher variant allele fraction and greater clonal complexity, along with higher mutant clonal burden and extensive chromosomal abnormalities; median survival after t-MN diagnosis was 0.9 months.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335902,1790156026,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":4},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","ARTICLE-Hematopoiesis  \nPrognostic relevance ofclonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy  \nZhuoer Xie,1,2 Terra Lasho,1 Arushi Khurana,1 Alejandro Ferrer,1 Christy Finke,1 Abhishek A. Mangaonkar,1 Stephen Ansell,1 Jenna Fernandez,1 Mithun Vinod Shah,1 Aref Al-Kali,1 Naseema Gangat,1 Jithma Abeykoon,1 Thomas E. Witzig1 and Mrinal M. Patnaik1  \n1 Mayo Clinic, Department of Internal Medicine, Hematology Division, Rochester, MN and 2 Malignant Hematology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA  \nAbstract  \nCorrespondence: M. Patnaik  \n[Patnaik. Mrinal@mayo.edu](Patnaik. Mrinal@mayo.edu)  \nReceived: June 13, 2023.  \nAccepted: August 16, 2023.  \nEarly view: August 31, 2023.  \n[https://doi.org/10.3324/haematol.2023.283727](https://doi.org/10.3324/haematol.2023.283727)  \n©2024 Ferrata Storti Foundation  \nPublished under a CC BY-NC license   \nWhile novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that: (i) CH is prevalent in relapsed follicular lymphoma and is associated with t-MN transformation, and (ii) radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the prevalence and prognostic impact of CH on clinical outcomes in 58 heavily pre-treated follicular lymphoma patients who received RIT. Patients had been given a median of four lines of therapy before RIT. The prevalence of CH prior to RIT was 46%, while it was 67%(P=0.15) during the course of RIT and subsequent therapies in the paired samples. Fourteen (24%) patients developed t-MN. Patients with t-MN had a higher variant allele fraction (38% vs. 15%; P=0.02) and clonal complexity (P=0.03) than those without. The spectrum of CH differed from that in age-related CH, with a high prevalence of DNA damage repair and response pathway mutations, absence of spliceosome mutations, and a paucity of signaling mutations. While there were no clear clinical associations between RIT and t-MN, or overall survival, patients with t-MN hada higher mutant clonal burden, along with extensive chromosomal abnormalities (median survival, afer t-MN diagnosis, 0.9 months) . The baseline prevalence of CH was high, with an increase in prevalence on exposure to RIT and subsequent therapies. The high rates of t-MN with marked clonal complexities and extensive chromosomal damage underscore the importance of better identifying and studying genotoxic stressors accentuated by therapeutic modalities.  \nIntroduction  \nClonal hematopoiesis (CH) is defined by the acquisition and subsequent expansion of somatic DNA variants, including somatic mutations and copy number alterations in hematopoietic stem and progenitor cells (HSPC) 1-4 When CH mutations occur in leukemia-associated genes, with a variant allele fraction (VAF) ≥2% in individuals without a diagnosed hematologic disorder, the condition is termed CH of indeterminant potential. While CH is ubiquitous with aging, context-specific development of CH is heterogeneous and dependent on clonal selection pressures. CH mutations have differential rates of fitness and stability and expand based on clonal selection pressures.5 Retrospective series have demonstrated the role of CH in therapy-related myeloid neoplasms (t-MN) and have  \ndocumented associations with inferior overall survival (OS) in the setting of prior cytotoxic therapies.6  \nCH of indeterminate potential is considered the first step in a multi-hit model for the development of t-MN.7 DNA-damage-inducing therapies such as chemotherapy or radiation used in primary cancers can lead to collateral alterations in HSPC, resulting in clonal populations with enhanced fitness and propagation potential,6,8,9 particularly whe","cbCairxaQauKlm1Q","https://ap.wps.com/l/cbCairxaQauKlm1Q","pdf",5077680,12,"English","# Abstract\n# Introduction\n# Methods\n## Cohort of patients","[{\"question\":\"What was the study hypothesis about clonal hematopoiesis and t-MN after RIT?\",\"answer\":\"The study hypothesized that clonal hematopoiesis is prevalent in relapsed follicular lymphoma, is associated with therapy-related myeloid neoplasms, and that radiation from radioimmunotherapy contributes to clonal progression and worsened outcomes.\"},{\"question\":\"How did CH prevalence change after radioimmunotherapy in this cohort?\",\"answer\":\"CH prevalence increased from 46% prior to RIT to 67% during RIT and subsequent therapies in paired samples.\"},{\"question\":\"What clinical and genomic features distinguished patients who developed t-MN?\",\"answer\":\"Patients with t-MN had a higher variant allele fraction and greater clonal complexity, along with higher mutant clonal burden and extensive chromosomal abnormalities; median survival after t-MN diagnosis was 0.9 months.\"}]","Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy - Abstract - Received June 13, 2023 | PDF",1790012784]